Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06962033 · ClinicalTrials.gov registry record · NA

PRIDE III Prison Interventions and HIV Prevention Collaboration

A NA study of HIV and Opioid Use, sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
300
Enrollment target
5
Study locations

NCT06962033 is a NA study of HIV and Opioid Use that is actively recruiting participants, run by Yale University. The registered enrollment target is 300 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (32% lower). The trial reports 5 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06962033, a NA study of HIV and Opioid Use, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
5
Study locations

Study Summary

The primary objective of this research project is to identify barriers to scale-up of Opioid Agonist Therapy (OAT) in the justice systems (prisons and probation) in Tajikistan, Kyrgyzstan, Moldova, and Georgia, and establish a NIATx learning collaborative to scale-up OAT, and analyze scale-up utilizing latent class growth analyses in people who inject drugs (PWID).

Conditions Studied

Interventions

  • BEHAVIORAL Opioid Agonist Therapy

Study Locations (5)

Other

  • Alternative Georgia - Tbilisi
  • AIDS Foundation East-West (AFEW) - Bishkek
  • NGO AFI - Chisinau
  • Institute for International Health and Education (IIHE) - Dushanbe

Connecticut

  • Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2024-11-05
Est. Completion 2028-12
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT06962033

The ClinicalTrials.gov registry entry for NCT06962033 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 439-participant average among 303 other HIV trials with a reported enrollment target (32% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Opioid Agonist Therapy is the first listed.

NCT06962033 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Other, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06962033 about?

NCT06962033 is a clinical study titled "PRIDE III Prison Interventions and HIV Prevention Collaboration". The primary objective of this research project is to identify barriers to scale-up of Opioid Agonist Therapy (OAT) in the justice systems (prisons and probation) in Tajikistan, Kyrgyzstan, Moldova, and Georgia, and establish a NIATx learning collaborative to scale-up OAT, and analyze scale-up utiliz...

What is the current status of trial NCT06962033?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2024-11-05. Estimated completion is 2028-12.

What conditions does trial NCT06962033 study?

This clinical trial studies the following conditions: HIV, Opioid Use.

What interventions are being tested in trial NCT06962033?

The interventions under investigation include: Opioid Agonist Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT06962033?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06962033 being conducted?

This trial has 5 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.